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Association studies between ADIPOR1 genetic variants and predisposition to type 2 diabetes (DM2) have provided contradictory
results. We determined if two single nucleotide polymorphisms (SNP c.-8503G>A and SNP c.10225C>G) in regulatory regions
of ADIPOR1 in 567 Brazilian individuals of European (EA; N = 443) or African (AfA; N = 124) ancestry from rural (quilombo
remnants; N = 439) and urban (N = 567) areas. We detected a significant effect of ethnicity on the distribution of the allelic
frequencies of both SNPs in these populations (EA: -8503A = 0.27; AfA: -8503A = 0.16; P = 0.001 and EA: 10225G = 0.35; AfA:
10225G = 0.51; P < 0.001). Neither of the polymorphisms were associated with DM2 in the case-control study in EA (SNP
c.-8503G>A: DM2 group -8503A = 0.26; control group -8503A = 0.30; P = 0.14/SNP 10225C>G: DM2 group 10225G = 0.37;
control group 10225G = 0.32; P = 0.40) and AfA populations (SNP c.-8503G>A: DM2 group -8503A = 0.16; control group -8503A
= 0.15; P = 0.34/SNP 10225C>G: DM2 group 10225G = 0.51; control group 10225G = 0.52; P = 0.50). Similarly, none of the
polymorphisms were associated with metabolic/anthropometric risk factors for DM2 in any of the three populations, except for
HDL cholesterol, which was significantly higher in AfA heterozygotes (GC = 53.75 ± 17.26 mg/dL) than in homozygotes. We
conclude that ADIPOR1 polymorphisms are unlikely to be major risk factors for DM2 or for metabolic/anthropometric
measurements that represent risk factors for DM2 in populations of European and African ancestries.
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Adiponectin is a circulating peptide secreted from adi-
pose tissue that acts as an antidiabetic adipokine (1). In
2003, two adiponectin receptors encoding genes were
described: adiponectin receptor 1 (ADIPOR1 ) and 2
(ADIPOR2 ) (2). Several case-control studies on single
nucleotide polymorphisms (SNPs) in the ADIPOR1 gene
and type 2 diabetes mellitus (DM2) have been conducted
in different populations but with contradictory results. Al-
though association has been found between polymor-
phisms at ADIPOR1 and DM2 in the Amish (3), all other
studies have been negative, including American (4), Japa-
nese (5), French (6), and UK populations (7). Interestingly,
associations between ADIPOR1 SNPs and liver fat con-
tent or insulin sensitivity (8), and with anthropometric meas-
urements, such as height, weight, body mass index (BMI)
(9), have been suggested.
In order to determine the association of ADIPOR1 with
susceptibility to DM2 and with anthropometric measure-
ments, we investigated if variants in regulatory regions of
ADIPOR1 (SNPs c.-8503G>A [rs6666089] in the promoter
and c.10225C>G [rs7539542] in the 3' UTR region) are
associated with DM2 or with anthropometric measure-
ments and also with metabolic traits in DM2 Brazilian
patients with European (EA) and African (AfA) ancestries
from both rural (quilombo remnants) and urban areas. We
also evaluated if the frequency of these SNPs differs
between individuals of EA and AfA.
The total sample consisted of 567 individuals: 313 from
a cohort being followed at the Federal University of Rio
Grande do Sul (UFRGS) (10) and 254 at the Hospital das
Clínicas of the Universidade de São Paulo (HC-USP).
Among them, 443 were EA (Portuguese, Spanish, Italian,
and German) descendants and 124 AfA (West Africa,
Angola, Mozambique) descendents (11,12). Patients were
evaluated using a questionnaire, physical examination
and laboratory tests. Diagnosis of DM2 was based on the
guidelines from the Expert Committee report (13). Weight
and height were measured without shoes and in light-
weight clothes; BMI was classified according to the World
Health Organization criteria (14). It was not possible to
obtain data for these parameters for all patients. The
reference group (control) consisted of 190 healthy DM2-
free blood donor volunteers at HC-USP (96 EA and 94 AfA,
age: 48.28 ± 16.39 years), who were previously described
by Errera et al. (11,12). The main clinical and laboratory
data are reported in Table 1 and were obtained as recom-
mended previously (11,12). A group of 439 non-diabetic
quilombo remnant individuals was also included. Previous
to the abolition of slavery in Brazil, many fugitive African
slaves founded communities called “Quilombos”. Currently,
population groups living in Quilombos are referred as
quilombo remnants, who are partially genetically isolated
(15). Data on systolic blood pressure, diastolic blood pres-
sure, height, weight, BMI, waist circumference, and plas-
ma glucose level were available for the quilombo remnant
individuals (15).
The Ethics Committees of the Instituto de Biociências-
USP, of HC-USP, and of UFRGS approved the study. All
subjects gave written informed consent.
Genomic DNA was extracted from peripheral blood
using standard protocols and amplified PCR. Both SNPs
were detected using SnuPE method (c.-8503G>A: 5'
AAATAGTATTATTTTATTCC 3' and c.10225C>G: 5' GAAA
TCTTTGAATGCCAAGT) and a Megabace DNA sequencer
Table 1. Clinical characteristics of type 2 diabetes mellitus patients of European ancestry and African ancestry, and of non-diabetic
individuals from quilombo remnant populations.
European ancestry African ancestry Quilombo remnants
Mean ± SD N Mean ± SD N Mean ± SD N
Age (years) 52.72 ± 15.08 443 50.22 ± 14.74 124 43.42 ± 17.57 439
Systolic blood pressure (mmHg) 142.2 ± 23.4 331 141.28 ± 24.1 51 127.32 ± 24.3 439
Diastolic blood pressure (mmHg) 85.67 ± 12.8 331 86.11 ± 12.3 51 82.92 ± 13.4 439
Body mass index (kg/m2) 28.5 ± 5.3 387 28.7 ± 5.4 105 24.8 ± 4.4 439
Waist circumference (cm) 98.0 ± 11.9 132 98.4 ± 12.6 26 83.2 ± 10.6 438
Total cholesterol (mg/dL) 210 ± 47.2 437 209 ± 78.2 105 NA
HDL cholesterol (mg/dL) 44.8 ± 12.9 437 49.6 ± 14.3 105 NA
LDL cholesterol (mg/dL) 133.8 ± 43.5 437 133.9 ± 47.5 105 NA
Serum creatinine (mg/dL) 1.31 ± 1.39 380 1.87 ± 2.57 94 NA
Triglycerides (mg/dL) 186.8 ± 146.7 437 142.2 ± 103.9 101 NA
HbA1C (%) 8.39 ± 2.6 304 9.22 ± 2.9 86 NA
Fasting plasma glucose (mg/dL) 176.4 ± 71.3 354 172.0 ± 67.9 94 97.63 ± 31.9 438
N = number of individuals for whom information was available. NA = data not available.
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(SNuPe, Amersham, Piscataway, NJ, USA).
Association studies were performed between a set of
315 DM2 patients (246 EA and 69 AfA) and the control
group, both within a comparable age range (mean age
DM2 patients: 52.39 ± 16.34 years; mean age control
group: 48.28 ± 16.39 years). Distribution of genotypes and
alleles was compared using the χ2 or the Fisher exact test.
The level of significance adopted was P < 0.05. Statistical
analyses were carried out with SSPS (Statistical Package
for the Social Sciences for Windows, version 10.0). Sam-
ple size power was calculated with PS Power and Sample
Size Calculations, version 2.1.30 (16).
Genotypic distributions for the SNPs c.-8503G>A and
c.10225C>G were in Hardy-Weinberg equilibrium in all
groups (P > 0.05).
Ethnicity had a significant effect on the distribution of
the allelic frequencies of these two SNPs in the DM2 and
control groups, in which the G allele of both SNPs was
more frequent in AfA than in EA (EA: -8503A = 0.27, AfA:
-8503A = 0.16, P = 0.001; EA: 10225G = 0.35; AfA:
10225G = 0.53, P < 0.001; Table 2).
There were no significant differences in genotypic and
allelic frequencies of SNPs -8503 and c.10225 between
DM2 patients and the control population: [EA (SNP
c.-8503G>A: DM2 group -8503A = 0.26; control group
-8503A = 0.30; P = 0.14; SNP 10225C>G: DM2 group
10225G = 0.37; control group 10225G = 0.32; P = 0.40)] or
[AfA (SNP c.-8503G>A: DM2 group -8503A = 0.16; control
group -8503A = 0.15; P = 0.34; SNP 10225C>G: DM2
group 10225G = 0.51; control group 10225G = 0.52; P =
0.50)], suggesting that these SNPs are not associated with
DM2 in these groups.
The effect of the genotypes on quantitative laboratory
data and anthropometric features of DM2 patients was
compared by the unpaired Student t-test and ANOVA.
These parameters were not associated with any genotype
of the SNP c.-8503G>A/ADIPOR1 [total cholesterol (EA: P
= 0.69; AfA: P = 0.50), HDL cholesterol (EA: P = 0.23; AfA:
P = 0.26), LDL cholesterol (EA: P = 0.85; AfA: P = 0.43),
serum creatinine (EA: P = 0.13; AfA: P = 0.89), triglycerides
(EA: P = 0.31; AfA: P = 0.31), systolic blood pressure (EA:
P = 0.83; AfA: P = 0.29), diastolic blood pressure (EA: P =
0.55; AfA: P = 0.95), HbA1c (EA: P = 0.16; AfA: P = 0.97),
plasma glucose (EA: P = 0.10; AfA: P = 0.28), height (EA:
P = 0.36; AfA: P = 0.90), weight (EA: P = 0.79; AfA: P =
0.15), BMI (EA: P = 0.92; AfA: P = 0.18), and waist
circumference (EA: P = 0.68; AfA: P = 0.91)].
In contrast, analysis of SNP 10225C>G in 156 DM2
patients with BMI information showed an association be-
tween the 10225G allele in EA and low BMI with borderline
level of significance (P = 0.037), but not with any other
parameter (data not shown). We genotyped an additional
Table 2. Genotypic frequencies of two ADIPOR1 gene single nucleotide polymorphisms (SNP) in the studied populations and P value
for different pairs of population comparisons.
SNP EA AfA Quilombo P value
    remnants
DM2 Control Total DM2 Control Total EA vs AfA Control vs DM2 AfA vs
Quilombo
In EA In AfA remmants
c.–8503G>A 0.001 0.14 0.34 -
GG 135 49 184 47 56 103 -
(54.9%) (51%) (53.8%) (68.1%) (71.8%) (70.1%)
AG 95 36 131 22 20 42 -
 (38.6%) (37.5%) (38.3%) (31.9%) (25.6%) (28.6%)
AA 16 11 27 0 2 2 -
(6.5%) (11.5%) (7.9%) (0%) (2.6%) (1.4%)
c.10225C>G <0.001 0.78 0.65 0.27
GG 51 9 60 29 20 49 126
(11.5%) (9.8%) (11.2%) (23.4%) (21.3%) (22.5%) (28.7%)
GC 196 40 236 69 59 128 207
(44.2%) (43.5%) (44.1%) (55.6%) (62.8%) (58.7%) (47.2%)
CC 196 43 239 26 15 41 106
(44.2%) (46.7%) (44.7%) (21%) (15.9%) (18.8%) (24.1%)
EA = European ancestry; AfA = African ancestry; DM2 = type 2 diabetes mellitus; Control = DM2-free blood donor volunteers.
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set of 207 DM2 subjects and the group of 439 non-diabetic
individuals from quilombo remnants (age: 43.42 ± 17.57
years) in order to increase the power of the study.
In the total sample of DM2 patients (N = 567), we
confirmed the lack of association between this SNP and
DM2 both in EA (DM2 group: 10225G = 0.34; control
group: 10225G = 0.31; P = 0.78) and AfA (DM2 group:
10225G = 0.51; control group: 10225G = 0.53; P = 0.65)
individuals. Except for HDL cholesterol, clinical and an-
thropometric features in DM2 [total cholesterol (EA: P =
0.31; AfA: P = 0.33), LDL cholesterol (EA: P = 0.17; AfA: P
= 0.11), serum creatinine (EA: P = 0.49; AfA: P = 0.89),
triglycerides (EA: P = 0.53; AfA: P = 0.49), systolic blood
pressure (EA: P = 0.43; AfA: P = 0.48), diastolic blood
pressure (EA: P = 0.25; AfA: P = 0.79), height (EA: P =
0.73; AfA: P = 0.90), weight (EA: P = 0.83; AfA: P = 0.58),
BMI (EA: P = 0.72; AfA: P = 0.86), waist circumference (EA:
P = 0.22; AfA: P = 0.74), HbA1c (EA: P = 0.42; AfA: P =
0.60), and plasma glucose (EA: P = 0.09; AfA: P = 0.74)]
were not associated with different genotypes of the SNP
c.10225C>G/ADIPOR1. Thus, the previous correlation we
found between allele 10225G and lower BMI was not
confirmed after increasing sample size. We observed that
HDL cholesterol was significantly higher in AfA heterozy-
gotes (GC = 53.75 ± 17.26 mg/dL) than in homozygotes
(CC = 44.75 ± 10.93 mg/dL; GG = 46.00 ± 12.52 mg/dL; P
= 0.02; of which, P = 0.06 between GC and CC genotypes,
P = 0.11 between GC and GG genotypes and P = 1.0
between CC and GG genotypes, after performing the post
hoc Bonferroni test). This association was not found with
EA (P = 0.49).
In quilombo remnant individuals, the allele frequency
of 10225G was 0.52. Clinical and anthropometric features
in these individuals were not associated with any genotype
of the SNP c.10225C>G/ADIPOR1 [systolic blood pres-
sure (P = 0.23), diastolic blood pressure (P = 0.42), height
(P = 0.66), weight (P = 0.27), BMI (P = 0.52), waist
circumference (P = 0.18), and plasma glucose level (P =
0.17)].
Thus, the present study characterizes for the first time
ADIPOR1 SNPs c.-8503G>A and c.10225C>G in groups
of the Brazilian population, including quilombo remnants.
The low allele frequency of both SNPs in our EA
sample (-8503A = 0.27 and 10225G = 0.32) was very
similar to the frequency found in American Caucasoid,
Finnish, German, French, UK, and HapMap Caucasian
populations (-8503A = 0.25-0.3 and 10225G = 0.31-0.33)
(4,6-9,17); but our SNP 10225G frequency was different
from Old Order Amish (-8503A = 0.27 and 10225G =
0.132) (3), probably because they represent an isolated
population. This result thus suggests that the Caucasian
population is relatively homogeneous worldwide for these
SNPs.
Although quilombo remnants form a semi-isolated popu-
lation (15), no significant difference in SNP c.10225C>G
minor allele frequency was found compared to the Brazil-
ian AfA groups. Minor allele frequency in our AfA sample
(-8503A = 0.16 and 10225G = 0.52) was different from that
in African-Americans (-8503A = 0.36 and 10225G = 0.42).
Different origins of African-derived populations in the US
and in Brazil or different proportions of admixture of the AfA
population in Brazil could explain this. These data indicate
the importance of analyzing EA and AfA separately in
case-control studies, as we have already suggested (12).
Moreover, the data suggest that these SNPs could repre-
sent valuable ancestry markers, which can be used to
distinguish between chromosomal segments of subjects of
AfA and EA.
We did not observe any association of ADIPOR1 SNPs
with DM2 in any of the groups studied here and with HbA1c
or BMI, which is consistent with several previous reports
(3-9). Siitonen et al. (9) reported an association of ADIPOR1
SNPs and some metabolic traits according to gender. Our
negative results cannot be explained by gender because
the genotype distribution did not differ between male and
female (data not shown).
The only positive significant association detected was
in the DM2 AfA group, in which SNP c.10225C>G het-
erozygotes showed significantly higher HDL cholesterol
levels than homozygotes. This cannot yet be explained at
the functional level, but it is known that adiponectin levels
correlate positively to HDL cholesterol levels and insulin-
stimulated glucose disposal (18,19). However, the differ-
ence found between heterozygotes and homozygotes (8.33
mg/dL) was lower than the minimum detectable difference
(9.67 mg/dL) with an acceptable power level (P > 0.8) in
this sample size. Hence, validation of these data in other
samples of African ancestry is necessary to exclude the
possibility of false positive.
Our data show that ADIPOR1 gene variants do not
represent major risk factors for DM2, increased BMI or any
of the traits analyzed in European and African descen-
dants, even though it should be noted that our sample size
had statistical power to detect 1.5 times or greater differ-
ence between groups for both populations. On the other
hand, these markers may be considered to be informative
markers for admixture mapping.
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